Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

Table 3 Comparison between patients with and without hepatosteatosis (mean ± SD)

Parameter	Steatosis (+)(n = 19)	Steatosis (-)(n = 65)	P value
Male	14 (73.07)	46 (70.8)	NS
Female	5 (26.3)	19 (29.2)	NS
Age (yr)	50.5 ± 8.7	35.2 ± 8.9	< 0.01
BMI (kg/m2)	32.9 ± 3.1	25.7 ± 3.3	< 0.01
≥ 25	18 (94.7)	38 (58.5)	< 0.01
Glucose (mg/dL)	102.7 ± 27.7	96.7 ± 19.0	NS
Cholesterol (mg/dL)	192.2 ± 28.0	178.0 ± 27.4	NS
Triglyceride (mg/dL)	188.3 ± 52.0	114.2 ± 44.2	< 0.01
AST (IU/L)	90.7 ± 34.8	107.0 ± 40.3	NS
ALT (IU/L)	128.3 ± 18.9	139.2 ± 52.5	< 0.01
GGT (IU/L)	49.8 ± 29.8	50.0 ± 44.0	NS
ALP (IU/L)	91.8 ± 26.3	91.9 ± 26.7	NS
HBV-DNA (copies/mL × 104)	5261.6 ± 2394.9	5684.2 ± 13245.8	NS
HBeAg (+)	4 (21.1)	17 (26.2)	NS
HBeAg (-)	15 (78.9)	48 (73.8)	NS
Advanced fibrosis (score ≥ 3)	8 (42.1)	27 (41.5)	NS
Advanced HAI (score ≥ 9)	6 (31.5)	17 (26.2)	NS
SVR	2 (10.5)	16 (24.6)	NS

BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ glutamyl transferase; ALP: Alkaline phosphatase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HAI: Histological activity index; SVR: Sustained viral response. NS: Non significant.